Immuron Stock

Immuron Debt 2024

Immuron Debt

-11.62 AUD

Ticker

IMC.AX

ISIN

AU000000IMC7

WKN

A0RDPK

In 2024, Immuron's total debt was -11.62 AUD, a -47.38% change from the -22.08 AUD total debt recorded in the previous year.

Immuron Aktienanalyse

What does Immuron do?

Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Immuron's Debt Structure

Immuron's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Immuron's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Immuron’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Immuron’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Immuron stock

What is the debt of Immuron this year?

Immuron has a debt level of -11.62 AUD this year.

What was the debt of Immuron compared to the previous year?

The debt of Immuron has increased by -47.38% compared to the previous year dropped.

What are the consequences of high debt for investors in Immuron?

High debt can pose a risk for investors of Immuron, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Immuron?

Low debt means that Immuron has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Immuron affect the company?

An increase in debt of Immuron can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Immuron affect the company?

A reduction in debt of Immuron can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Immuron?

Some factors that can influence the debt of Immuron include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Immuron so important for investors?

The debts of Immuron are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Immuron take to change the debt?

To change the debt, Immuron can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Immuron pay?

Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.

What is the dividend yield of Immuron?

The current dividend yield of Immuron is .

When does Immuron pay dividends?

Immuron pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immuron?

Immuron paid dividends every year for the past 0 years.

What is the dividend of Immuron?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immuron located?

Immuron is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immuron from 11/5/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Immuron pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Immuron in the year 2023?

In the year 2023, Immuron distributed 0 AUD as dividends.

In which currency does Immuron pay out the dividend?

The dividends of Immuron are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immuron

Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.